Acadian Asset Management’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-940,396
| Closed | -$63.8M | – | 2182 |
|
|
2019
Q3 | $63.8M | Sell |
940,396
-97,256
| -9% | -$6.68M | 0.27% | 97 |
|
|
2019
Q2 | $60.4M | Buy |
1,037,652
+144,538
| +16% | +$8.56M | 0.29% | 91 |
|
|
2019
Q1 | $62.6M | Buy |
893,114
+151,846
| +20% | +$11.3M | 0.27% | 96 |
|
|
2018
Q4 | $47.7M | Buy |
741,268
+215,892
| +41% | +$15.1M | 0.24% | 110 |
|
|
2018
Q3 | $36.9M | Buy |
525,376
+278,516
| +113% | +$16.3M | 0.15% | 142 |
|
|
2018
Q2 | $12.4M | Buy |
246,860
+212,531
| +619% | +$8.43M | 0.05% | 265 |
|
|
2018
Q1 | $1.07M | Buy |
34,329
+30,154
| +722% | +$1M | ﹤0.01% | 715 |
|
|
2017
Q4 | $143K | Sell |
4,175
-759
| -15% | -$24.2K | ﹤0.01% | 1021 |
|
|
2017
Q3 | $158K | Sell |
4,934
-18,221
| -79% | -$575K | ﹤0.01% | 951 |
|
|
2017
Q2 | $753K | Buy |
+23,155
| New | +$733K | ﹤0.01% | 752 |
|
|
2017
Q1 | – | Sell |
-19,172
| Closed | -$564K | – | 1876 |
|
|
2016
Q4 | $564K | Sell |
19,172
-250,830
| -93% | -$7.65M | ﹤0.01% | 837 |
|
|
2016
Q3 | $7.81M | Sell |
270,002
-254,902
| -49% | -$7.1M | 0.04% | 304 |
|
|
2016
Q2 | $13.6M | Sell |
524,904
-22,393
| -4% | -$595K | 0.07% | 221 |
|
|
2016
Q1 | $13.6M | Buy |
547,297
+466,765
| +580% | +$12.8M | 0.07% | 238 |
|
|
2015
Q4 | $2.83M | Buy |
+80,532
| New | +$2.16M | 0.01% | 510 |
|
|
2015
Q1 | – | Sell |
-2,824
| Closed | -$90K | – | 1506 |
|
|
2014
Q4 | $90K | Buy |
+2,824
| New | +$91.9K | ﹤0.01% | 1014 |
|
Acadian Asset Management's GHDX Position: Q4 2019 in Review
Acadian Asset Management sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 940,396 shares — an estimated $63.8M sold.
Acadian Asset Management first reported a position in GHDX in Q4 2014 and held it in 16 quarters. The position peaked at $63.8M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Acadian Asset Management reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Acadian Asset Management sold 940,396 Genomic Health, Inc. shares in Q4 2019, an estimated $63.8M.
- Acadian Asset Management first reported a position in Genomic Health, Inc. in Q4 2014 and held it in 16 quarters.
- Acadian Asset Management's Genomic Health, Inc. position peaked at $63.8M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Acadian Asset Management's 13F filing for Q4 2019, filed 6 Feb 2020.